Farmacoepidemiologia

Esiti neonatali e criteri di rimborso per il palivizumab

A. Addis, V. Belleudi, F. Trotta, L. Pinnarelli, M. Davoli

2018/10 — pag. 636-640

In 2016 the Italian Medicines Agency (AIFA) decided to limit the coverage of the prophylaxis with palivizumab following the American Academy of Pediatrics guidelines. In 2017 as a consequence of the strong debate that involved scientific societies, p...

Profilo epidemiologico delle ADR in pediatria

A. Clavenna, M. Bonati

2009/8 — pag. 501-507

A meta-analysis of 8 prospective studies performed in the United States and Europe in the 2001-2007 period estimated that the incidence of ADRs in hospitalised children is 10.9% and in paediatric outpatients 1.0%. The contribution of ADRs to the ho...

Profilo prescrittivo dei farmaci antiasmatici nella popolazione pediatrica della ASL di Lecco

M. Bianchi, A. Clavenna, L. Labate, A. Bortolotti, I. Fortino, G.W. Locatelli, G. Giuliani, M. Bonati

2007/10 — pag. 653-659

Antiasthmatic drugs are often prescribed for conditions different from asthma and many patients are exposed to therapy for which there is no evidence of efficacy. The aim of this study was to test whether antiasthmatic drug prescription rates refle...

La prescrizione di farmaci soggetti a nota nella popolazione pediatrica italiana.

S. Maschi, A. Clavenna, E. Rossi, A. Berti, M. De Rosa, M. Bonati

2005/7

La prescrizione di farmaci soggetti a Nota nella popolazione pediatrica italiana

S. Maschi, A. Clavenna, E. Rossi, et al.

2005/7 — pag. 475-477

The objectives of the study are to evaluate the pattern of drug prescriptions reimbursed with limitations (AIFA notes) by the National Health System in the Italian paediatric population. Prescriptions involving 982,035 children ...